Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models

Ashok Iyaswamy*, Xueli Wang, Senthilkumar Krishnamoorthi, Venkatapathy Kaliamoorthy, Sravan G. Sreenivasmurthy, Siva Sundara Kumar Durairajan, Ju Xian Song, Benjamin Chun kit Tong, Zhou Zhu, Cheng Fu Su, Jia Liu, King Ho Cheung, Jia Hong Lu, Jie Qiong Tan, Hung Wing Li*, Man Shing Wong*, Min Li*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Accumulation of amyloid-β (Aβ) oligomers and phosphorylated Tau aggregates are crucial pathological events or factors that cause progressive neuronal loss, and cognitive impairments in Alzheimer's disease (AD). Current medications for AD have failed to halt, much less reverse this neurodegenerative disorder; therefore, there is an urgent need for the development of effective and safe drugs for AD therapy. In the present study, the in vivo therapeutic efficacy of an Aβ-oligomer-targeted fluorescent probe, F-SLOH, was extensively investigated in 5XFAD and 3XTg-AD mouse models. We have shown that F-SLOH exhibits an efficient inhibitory activity against Aβ aggregation in vivo, and acts as an effective theranostic agent for the treatment of multiple neuropathological changes in AD mouse models. F-SLOH has been found to significantly reduce not only the levels of Aβ oligomers, Tau aggregates and plaques but also the levels of amyloid precursor protein (APP) and its metabolites via autophagy lysosomal degradation pathway (ALP) in the brains of 5XFAD and 3XTg-AD mice. It also reduces astrocyte activation and microgliosis ultimately alleviating neuro-inflammation. Furthermore, F-SLOH mitigates hyperphosphorylated Tau aggregates, synaptic deficits and ameliorates synaptic memory function, and cognitive impairment in AD mouse models. The mechanistic studies have shown that F-SLOH promotes the clearance of C-terminal fragment 15 (CTF15) of APP and Paired helical filaments of Tau (PHF1) in stable cell models via the activation of transcription factor EB (TFEB). Moreover, F-SLOH promotes ALP and lysosomal biogenesis for the clearance of soluble, insoluble Aβ, and phospho Tau. Our results unambiguously reveal effective etiological capabilities of theranostic F-SLOH to target and intervene multiple neuropathological changes in AD mouse models. Therefore, F-SLOH demonstrates tremendous therapeutic potential for treating AD in its early stage.
Original languageEnglish
Article number102280
Number of pages21
JournalRedox Biology
Volume51
DOIs
Publication statusPublished - May 2022

Scopus Subject Areas

  • Organic Chemistry
  • Clinical Biochemistry

User-Defined Keywords

  • 3XTg-AD
  • 5XFAD
  • Alzheimer's disease
  • Aβ-aggregate inhibition
  • Aβ-targeting
  • Theranostic

Fingerprint

Dive into the research topics of 'Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models'. Together they form a unique fingerprint.

Cite this